Specimen Collection Cards Market - Strategic Insights and Forecasts (2026-2031)

The Specimen Collection Cards Market is projected to register a strong CAGR during the forecast period (2026-2031).

The specimen collection cards market represents a foundational segment of the global diagnostic and screening ecosystem, enabling the collection, transport, and storage of biological samples under ambient conditions. These cards are primarily used for collecting dried blood spots and other micro-samples, offering logistical advantages over liquid sample formats by eliminating cold-chain requirements and reducing biohazard risks. Historically, newborn screening programs have been the primary growth driver, but applications have broadened to include infectious disease testing, forensic analysis, therapeutic drug monitoring, and population-scale research initiatives.

Advances in analytical sensitivity and molecular diagnostics have expanded the functional role of specimen collection cards from passive carriers to engineered sampling devices. Features such as chemical impregnation for nucleic acid stabilization, integrated identifiers, and compatibility with automated laboratory systems have increased their relevance in modern diagnostic workflows. At the same time, sustainability considerations and operational efficiency are shaping product development and procurement decisions across healthcare systems.

Market Dynamics

Market Drivers

• Expansion of Mandatory Newborn Screening (NBS): The central driver is the global increase in the number of metabolic and genetic conditions screened at birth. These programs require massive volumes of standardized, validated dried blood spot cards.

• Rise of Personalized Medicine: Pharmacogenomics and longitudinal sampling rely on stable access to patient DNA. Specimen collection cards provide a practical, cost-effective solution for gathering these samples outside of traditional hospital settings.

• Technological Improvements in Microsampling: As downstream assays require smaller volumes, card-based sampling is replacing conventional venipuncture, particularly for pediatric and geriatric populations where invasive draws are difficult.

• Infectious Disease Surveillance: Global health initiatives for monitoring HIV, Hepatitis, and emerging viral threats utilize collection cards to facilitate testing in regions with limited refrigeration or laboratory infrastructure.

Market Restraints and Opportunities

• Specimen collection cards face challenges such as variability in absorption characteristics and analyte recovery across different paper grades. Inconsistent sample distribution can affect quantitative accuracy in high-precision applications. Furthermore, integration with legacy laboratory workflows and a reliance on a limited number of specialty fiber suppliers create potential bottlenecks. However, significant opportunities exist in the transition to "patient-centric" kits that bundle cards with lancets and return-shipping materials. Growing investments in large-scale biobanking and the expansion of Direct-to-Consumer (DTC) genetic testing increase the need for advanced stabilization platforms. As decentralized clinical trials become the norm, these cards can emerge as the primary bridge between remote participants and centralized research facilities.

Raw Material and Pricing Analysis

Specimen collection cards are manufactured using high-purity cellulose linters or engineered fiber materials that meet stringent medical and analytical requirements. These raw materials must be free from contaminants and additives that could interfere with molecular assays, placing constraints on sourcing and processing. As a result, raw material costs represent a significant component of overall pricing.

Pricing is also influenced by value-added treatments, such as chemical impregnation for cell lysis and nucleic acid stabilization. Cards incorporating these technologies command higher prices than untreated filter paper due to additional processing steps and quality controls. Fluctuations in pulp supply, energy costs, and specialty chemical availability can contribute to pricing variability, particularly in regions with concentrated production capacity.

Manufacturers are increasingly investing in process automation and sustainable sourcing to manage costs over the long term. While these investments may increase capital expenditure, they are intended to improve yield consistency and reduce operational risks associated with labor and supply chain volatility.

Supply Chain Analysis

The supply chain for specimen collection cards is relatively specialized, with a limited number of manufacturers capable of producing medical-grade, standardized materials at scale. Advanced production facilities are primarily located in North America and parts of Europe, where expertise in cellulose treatment, coating, and precision printing is well established.

Downstream distribution benefits from the inherent stability of dried samples, allowing cards to be shipped and stored using standard logistics channels. This reduces transportation complexity compared to liquid samples and supports global deployment, including in low-resource settings. However, reliance on a small number of standard-setting suppliers introduces concentration risk, particularly for high-volume applications such as newborn screening.

To mitigate these risks, manufacturers are pursuing vertical integration and long-term supply agreements. These strategies aim to secure access to critical inputs while improving coordination between material production, card conversion, and final packaging.

Government Regulations

Key Developments

• October 2025: Ahlstrom completed the acquisition of Eastern Business Forms (EBF), a specialist in manufacturing 903-grade diagnostic cards. This integration strengthens Ahlstrom’s ability to provide fully converted and printed specimen collection solutions for the global newborn screening market.

• April 2025: QIAGEN announced that its QIAsprint Connect system, designed for automated high-throughput sample processing, is on track for a 2026 launch. The system aims to reduce plastic waste and manual handling in laboratories.

• March 2025: Revvity was awarded a significant contract to provide screening services and consumables for rare diseases in the UK. The deal underscores the demand for high-quality, standardized collection cards in national health programs.

• February 2025: Ahlstrom announced that its GenSaver™ 2.0, HemaSep™, and other collection cards were listed as FDA Class 1 medical devices. This confirms the products meet US regulatory requirements for safety and quality in clinical diagnostics.

Market Segmentation

By Application: Newborn Screening (NBS)

Newborn screening remains the most established and volume-intensive application for specimen collection cards. Public health mandates require universal screening shortly after birth, creating predictable and recurring demand for high-quality dried blood spot cards. These cards must meet strict criteria for absorbency, uniformity, and analyte stability to support accurate detection of metabolic and genetic disorders.

Recent expansions of screening panels to include conditions such as spinal muscular atrophy and severe combined immunodeficiency have increased analytical complexity. As a result, screening laboratories are placing greater emphasis on card performance and traceability. Barcoded and pre-labeled cards are increasingly adopted to reduce handling errors and improve integration with laboratory information systems.

By End-User: Hospitals and Clinics

Hospitals and clinics represent the primary point of specimen collection for both screening and diagnostic applications. In these settings, workflow efficiency and compliance with clinical protocols are key considerations. Integrated collection kits that bundle cards with lancets and packaging materials are gaining traction, as they simplify procurement and reduce preparation time for clinical staff.

The integration of electronic health records has also influenced card design and selection. Cards featuring scannable identifiers enable real-time sample registration and tracking, supporting faster turnaround times and improved data integrity. These features are particularly relevant in high-throughput environments where sample volumes are large and operational margins are tight.

Regional Analysis

North America Market Analysis

North America is the most mature region for specimen collection cards, driven by the United States' comprehensive newborn screening programs and a massive diagnostic laboratory infrastructure. The focus on decentralized clinical trials and the formalization of FDA Class 1 listings for collection cards have solidified the market. Organizations are prioritizing high-throughput, barcoded cards to manage complex regulatory obligations and large-scale population health studies.

South America Market Analysis

South American markets, led by Brazil, are ramping up focus on public health programs. Brazil’s investment in the National Newborn Screening Program expansion is a major driver. Large healthcare providers are experimenting with card-based sampling to manage remote patient populations in the Amazon basin and other geographically challenging areas, where cold-chain logistics are non-existent.

Europe Market Analysis

The implementation of the In Vitro Diagnostic Regulation (IVDR) in Europe has established a high bar for card manufacturers. Germany and the UK are leading the market through the adoption of high-automation laboratory systems. The European Union’s digital health strategy promotes the use of standardized collection tools to ensure data integrity across borders, making Europe a leader in specialized, high-performance cards for biobanking.

Middle East and Africa Market Analysis

This region shows significant growth potential, particularly in the Gulf countries. Saudi Arabia and the UAE are investing in national genomic visions. Specimen collection cards play a vital role in these initiatives, facilitating the collection of thousands of samples for population-scale sequencing. In Africa, cards remain a foundational tool for infectious disease surveillance (HIV/Malaria) due to their ambient stability.

Asia Pacific Market Analysis

The Asia-Pacific region is the fastest-growing market due to strong digital health adoption and the expansion of healthcare access in India and China. Japan leads in developing standards for high-purity medical fibers. In India, the rapid rise of the tele-diagnostic sector has created high demand for self-collection kits that use specimen cards to optimize the logistics of rural-to-urban sample flow.

List of Companies

• Ahlstrom

• Danaher Corporation (Pall / Beckman Coulter)

• PerkinElmer, Inc.

• Merck KGaA (Sigma-Aldrich)

• Thermo Fisher Scientific

• QIAGEN

• Noviphi Diagnostics

• Eastern Business Forms (Ahlstrom)

• Centogene N.V.

• GenTegra LLC

Ahlstrom

Ahlstrom is recognized globally as an authority on specialty fiber materials. Their specimen collection platforms enable the continuous movement of biological data from the point of care to the laboratory. Following the acquisition of Eastern Business Forms, the company has consolidated its position in the newborn screening market. Their system gathers capacity from high-purity cellulose to create a consistent, absorbent medium that ensures sample uniformity. Ahlstrom has deployed its medical-grade cards across multiple continents to support the modernization of global screening grids.

PerkinElmer, Inc.

PerkinElmer focuses on providing end-to-end solutions for newborn screening and clinical diagnostics. They specialize in integrating collection cards with analytical hardware. By using these tools, the company provides a distributed resource for health departments, including automated punchers and reagent kits designed specifically for their proprietary card formats. PerkinElmer has established partnerships with global health ministries to develop pilot programs for expanded metabolic screening, providing the infrastructure necessary for modern public health ecosystems.

Thermo Fisher Scientific

Thermo Fisher provides a vast range of specimen collection tools orchestrated through its global distribution network. In the context of collection cards, their products are used to forecast sample demand and optimize laboratory workflows. Their chemically treated cards can coordinate large-scale forensic and genomic studies, participating in services like DNA database management and real-time viral load monitoring. The company participates in global health modernization initiatives where advanced sample stabilization tools support the integration of remote research and smarter, cloud-native diagnostic systems.

Specimen Collection Cards Market Scope: